Synta Pharmaceuticals announced final results from the GALAXY-1 trial for ganetespib in patients with advanced non-small lung cancer (NSCLC) with adenocarcinoma histology most likely to benefit from second-line treatment. Ganetespib is a selective inhibitor of heat shock protein 90 (Hsp90), a molecular chaperone which controls the folding and activation of a number of client proteins that drive tumor development and progression.
GALAXY-1 was a randomized, multi-center study designed to identify patient populations that are most responsive to treatment with the combination of ganetespib and docetaxel. Co-primary endpoints of the study were progression free survival (PFS) in patients with elevated LDH (eLDH) and PFS in patients with mutant KRAS (mKRAS).
RELATED: Lung Cancer Resource Center
Continue Reading
Prespecified stratification factor analysis has shown that the chemosensitive patient population, the patients diagnosed with advanced NSCLC more than 6 months prior to study entry, derived the most benefit with combination treatment. This chemosensitive population was selected for the ongoing Phase 3 GALAXY-2 trial.
For more information call (781) 274-8200 or visit Syntapharma.com.
This article originally appeared on MPR
